Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer

Journal of the National Cancer Institute

Volumn 100, Issue 3, 2008, Pages 207-212

  Viale, Giuseppe ^a,o   Regan, Meredith M ^b   Mastropasqua, Mauro G ^a   Maffini, Fausto ^a   Maiorano, Eugenio ^c   Colleoni, Marco ^a   Price, Karen N ^b   Golouh, Rastko ^d   Perin, Tiziana ^e   Brown, R W ^f   Kovács, Anikó ^g   Pillay, Komala ^h   Öhlschlegel, Christian ⁱ   Gusterson, Barry A ^j   Castiglione Gertsch, Monica ^k   Gelber, Richard D ^b   Goldhirsch, Aron ^a,l   Coates, Alan S ^m,n  

^a UNIVERSITY OF MILAN   (Italy)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c UNIVERSITY OF BARI   (Italy)

^d INSTITUTE OF ONCOLOGY   (Slovenia)

^e CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^f MELBOURNE PATHOLOGY   (Australia)

^g SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^h UNIVERSITY OF CAPE TOWN   (South Africa)

ⁱ SWISS GROUP FOR CLINICAL CANCER RESEARCH SAKK   (Switzerland)

^j UNIVERSITY OF GLASGOW   (United Kingdom)

^k IBCSG Coordinating Center   (Switzerland)

^l ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

^m IBCSG   (Switzerland)

ⁿ UNIVERSITY OF SYDNEY   (Australia)

^o International Breast Cancer Study Group Coordinating Center   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; FLUOROURACIL; GOSERELIN; KI 67 ANTIGEN; METHOTREXATE; TAMOXIFEN; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; CMF REGIMEN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; ANTIBODY LABELING; ANTIGEN EXPRESSION; ARTICLE; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE FREE SURVIVAL; DRUG DOSE SEQUENCE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; SURVIVAL TIME; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; ADJUVANT CHEMOTHERAPY; AGED; ANALYSIS OF VARIANCE; BREAST TUMOR; CHEMISTRY; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PREDICTION AND FORECASTING; RETROSPECTIVE STUDY; STATISTICAL MODEL;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; FEMALE; FLUOROURACIL; HUMANS; KI-67 ANTIGEN; LOGISTIC MODELS; METHOTREXATE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; TAMOXIFEN; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 39149102890     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djm289     Document Type: Article

References (29)

1. Mandard AM, Denoux Y, Herlin P, et al. Prognostic value of DNA cytometry in 281 premenopausal patients with lymph node negative breast carcinoma randomized in a control trial: multivariate analysis with Ki-67 index, mitotic count, and microvessel density. Cancer. 2000;89:1748-1757.
2. Clahsen PC, Van de V, Duval C, et al. The utility of mitotic index, oestrogen receptor and Ki-67 measurements in the creation of novel prognostic indices for node-negative breast cancer. Eur J Surg Oncol. 1999;25:356-363.
3. Gerdes J, Schwab U, Lemke H, Stein H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer. 1983;31:13-20.
4. Lehr HA, Hansen DA, Kussick S, et al. Assessment of proliferative activity in breast cancer: MIB-1 immunohistochemistry versus mitotic figure count. Hum Pathol. 1999;30:1314-1320.
5. Thor AD, Liu S, Moore DH, Edgerton SM. Comparison of mitotic index, in vitro bromodeoxyuridine labeling, and MIB-1 assays to quantitate proliferation in breast cancer. J Clin Oncol. 1999;17:470-477.
6. Sahin AA, Ro J, Ro JY, et al. Ki-67 immunostaining in node-negative stage I/II breast carcinoma. Significant correlation with prognosis. Cancer. 1991;68:549-557.
7. Domagala W, Markiewski M, Harezga B, Dukowicz A, Osborn M. Prognostic significance of tumor cell proliferation rate as determined by the MIB-1 antibody in breast carcinoma: its relationship with vimentin and p53 protein. Clin Cancer Res. 1996;2:147-154.
8. Pietilainen T, Lipponen P, Aaltomaa S, Eskelinen M, Kosma VM, Syrjanen K. The important prognostic value of Ki-67 expression as determined by image analysis in breast cancer. J Cancer Res Clin Oncol. 1996;122:687-692.
9. Trihia H, Murray S, Price K, et al. Ki-67 expression in breast carcinoma. Cancer. 2003;97:1321-1331.
10. Jansen RL, Hupperets PS, Arends JW, et al. MIB-1 labelling index is an independent prognostic marker in primary breast cancer. Br J Cancer. 1998;78:460-465.
11. Chang J, Ormerod M, Powles TJ, Allred DC, Ashley SE, Dowsett M. Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma. Cancer. 2000;89:2145-2152.
12. Archer CD, Parton M, Smith IE, et al. Early changes in apoptosis and proliferation following primary chemotherapy for breast cancer. Br J Cancer. 2003;89:1035-1041.
13. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thürlimann B, Senn HJ. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol. 2005;16:1569-1583.
14. International Breast Cancer Study Group. Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial. J Natl Cancer Inst Cancer Spectrum. 2003;95:1833-1846.
15. International Breast Cancer Study Group. Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph nodenegative breast cancer: a randomized trial. J Natl Cancer Inst. 2002;94:1054-1065.
16. Bloom H, Richardson W. Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer. 1957;11(3):359-377.
17. Regan MM, Viale G, Mastropasqua MG, et al. Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays. J Natl Cancer Inst. 2006;98:1571-1581.
18. Jacobs TW, Gown AM, Yaziji H, Barnes MJ, Schnitt SJ. Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. J Clin Oncol. 1999;17:1983-1987.
19. Viale G, Regan MM, Maiorano E, et al. Chemo-endocrine versus endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors. J Clin Oncol. In press.
20. Birner P, Oberhuber G, Stani J, et al. Evaluation of the United States Food and Drug Administration-approved scoring and test system of HER-2 protein expression in breast cancer. Clin Cancer Res. 2001;7:1669-1675.
21. Bonetti M, Gelber RD. A graphical method to assess treatment-covariate interactions using the Cox model on subsets of the data. Stat Med. 2000;19(19): 2595-2609.
22. de Azambuja E, Cardoso F, de Castro G Jr, et al. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients. Br J Cancer. 2007;96:1504-1513.
23. Offersen BV, Sorensen FB, Knoop A, Overgaard J. The prognostic relevance of estimates of proliferative activity in early breast cancer. Histopathology. 2003;43:573-582.
24. Colozza M, Azambuja E, Cardoso F, Sotiriou C, Larsimont D, Piccart MJ. Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now? Ann Oncol. 2005;16:1723-1739.
25. MacGrogan G, Mauriac L, Durand M, et al. Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST pi. Br J Cancer. 1996;74:1458-1465.
26. Assersohn L, Salter J, Powles TJ, et al. Studies of the potential utility of Ki67 as a predictive molecular marker of clinical response in primary breast cancer. Breast Cancer Res Treat. 2003;82:113-123.
27. Bottini A, Berruti A, Bersiga A, et al. Relationship between tumour shrinkage and reduction in Ki67 expression after primary chemotherapy in human breast cancer. Br J Cancer. 2001;85:1106-1112.
28. Colleoni M, Zahrieh D, Gelber RD, et al. Preoperative systemic treatment: prediction of responsiveness. Breast. 2003;12:538-542.
29. Chang J, Powles TJ, Allred DC, et al. Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. J Clin Oncol. 1999;17:3058-3063.